Article

Sustained resolution of fibrosing cholestatic hepatitis C despite viremic relapse after stopping pegylated interferon and ribavirin therapy

Division of Gastroenterology & Hepatology, Saint Louis University, Сент-Луис, Michigan, United States
Liver Transplantation (Impact Factor: 4.24). 02/2007; 13(2):309-11; author reply 312. DOI: 10.1002/lt.21019
Source: PubMed
1 Follower
 · 
57 Views
 · 
0 Downloads
  • Source
    • "One of the key reasons for identifying and separating this entity is that allograft injury is rapidly progressive , and may result in allograft failure within months of onset. It is usually resistant to antiviral therapy, although isolated reports of successful outcomes have been observed [4] [5]. One case of HCV clearance has been reported following significant reduction in immunosuppressive therapy [6]. "
    Journal of Hepatology 02/2011; 54(2):392-4. DOI:10.1016/j.jhep.2010.09.010 · 10.40 Impact Factor
  • Source
    • "NR NR Gopal et al. 34 (2001) 6.4 (median) NR 261 (median) Takahashi et al. 49 (2003) 7.9 1153 75 Gopal and Rosen 45 (2003) 10.7 6 5.4 NR 279 6 203 Neff et al. 39 (2005) 15.7 NR 480 Castells et al. 50 (2006) 16, 21, 18 185, 256, 294 290, 440, 296 Taniguchi et al. 30 (2006) NR NR 110 Sohara et al. 42 (2006) 7.9 1153 75 Bolkhir et al. 43 (2007) 12.3 500 700 Carrion et al. 48 (2007) "
    [Show abstract] [Hide abstract]
    ABSTRACT: Liver transplantation is currently the only definitive modality for the treatment of end-stage liver disease due to chronic hepatitis C. However, recurrent hepatitis C after liver transplantation is nearly universal. Cirrhosis may develop in 20% of recipients within 5 years, and recurrent hepatitis C may lead to graft failure, retransplantation, and even death. A subset of recipients may develop post-liver transplant cholestatic hepatitis C (PLTCHC), which is characterized by cholestasis, hepatocyte ballooning, and rapid progression to graft failure. We present a systematic review of PLTCHC that is focused on hepatitis C-infected liver transplant recipients. We compare the pathological definitions of PLTCHC, clinical factors, management strategies, and outcomes reported in studies. We found differences among studies in the types of histological criteria used to diagnose PLTCHC during liver biopsy and in the types of clinical information provided. Three of the 12 studies published after 2003 used the definition of PLTCHC published by the first International Liver Transplantation Society expert panel consensus conference on liver transplantation and hepatitis C. We propose that studies on PLTCHC use the consensus criteria for diagnosis and suggest clinical information that should be provided in future studies with the goal of improving our understanding and management of this deadly disease.
    Liver Transplantation 11/2010; 16(11):1228-35. DOI:10.1002/lt.22175 · 4.24 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Fibrosing cholestatic hepatitis (FCH) is the most devastating manifestation of recurrent hepatitis C in transplant recipients with hepatitis C virus (HCV), possibly leading to death or retransplantation. Although FCH was first described as a complication of hepatitis B, this manifestation has been well documented in association with HCV in the setting of liver transplantation, bone marrow transplantation, heart transplantation, and end-stage human immunodeficiency virus infection. We report the clinical course and antiviral response in a patient with FCH due to recurrent hepatitis C after cadaveric liver transplantation who was treated with pegylated interferon alpha-2a and ribavirin.
    The Korean Journal of Hepatology 01/2009; 14(4):519-24. DOI:10.3350/kjhep.2008.14.4.519
Show more

Preview

Download
0 Downloads